A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

This study is looking for adults aged 18 or older who have been living with chronic eczema (atopic dermatitis) for at least one year. Your eczema needs to be considered moderate to severe by the study doctor. This means it affects a significant area of your body, causes noticeable itchiness, and has been given a particular severity score by the doctor.

You might be a good fit if your current eczema treatments, like creams or ointments, haven't worked well enough, or if those treatments cause problems for you and your doctor thinks you should consider stronger medicines. You also need to be generally healthy apart from your eczema.

However, there are some reasons why you might not be able to join. For example, if you have other serious health conditions, especially certain bowel diseases, or if you've had frequent serious infections recently, you wouldn't be able to take part. Also, if you have other skin conditions that might make it hard to tell if the eczema is improving, you wouldn't be eligible.

If you decide to take part, you would receive either the new medicine, Galvokimig, or a placebo, which is a dummy medicine. You wouldn't know which one you're getting. You would have regular visits to the study clinic where doctors and nurses would check your eczema, measure your symptoms like itching and skin redness, and take blood samples. They would also do general health checks and ask questions about how you're feeling to monitor your safety. The total length of your participation in the study and the number of visits would be explained in detail by the study team, but these types of studies often involve several months of regular appointments, followed by a period where your health is monitored.